ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Down 0.4% – What’s Next?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)’s share price was down 0.4% during trading on Wednesday . The stock traded as low as $46.40 and last traded at $46.59. Approximately 24,274 shares changed hands during trading, an increase of 28% from the average daily volume of 18,918 shares. The stock had previously closed at $46.80.

ALPS Medical Breakthroughs ETF Price Performance

The company’s 50-day moving average price is $41.84 and its two-hundred day moving average price is $35.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Comerica Bank bought a new position in ALPS Medical Breakthroughs ETF during the third quarter valued at about $27,000. Raymond James Financial Inc. bought a new stake in ALPS Medical Breakthroughs ETF in the second quarter valued at about $82,000. Ally Invest Advisors Inc. bought a new stake in shares of ALPS Medical Breakthroughs ETF in the second quarter worth about $200,000. Moran Wealth Management LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the second quarter worth $300,000. Finally, Sterling Investment Advisors Ltd. bought a new stake in ALPS Medical Breakthroughs ETF in the 3rd quarter valued at approximately $315,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.